(Photo: http://www.

Business Editors /Medical Editors

DELFT, Netherlands----Bruker AXS,
Inc., a leading global provider of advanced X-ray solutions for life
sciences and advanced materials research, announces today the
establishment of a new laboratory in Delft, equipped with the latest
state-of-the-art X-ray instrumentation and technologies for the
determination of 3D crystal structures of small molecules and
proteins.
These and other factors are identified and described in more detail in
our filings with the SEC, including , without limitation, our
respective annual reports on Form 10-K for the year ended December 31,
2004 , our most recent quarterly reports on Form 10-Q, and our current
reports on Form 8-K.

ifo amorphous

FXR, a bile acid sensor and regulator of bile acid homeostasis, is
an emerging target with therapeutic potential for the modulation of
cholesterol and triglyceride levels.
"Our Protein Portfolio represents an increasingly valuable resource for
drug development.

pdf2text umwege

We hope to push
the boundaries of existing technologies in structural proteomics and
crystallography through extensive collaborations with leading
investigators."
Professor Jan Pieter Abrahams, Project Leader of the Cyttron
research project , 'A Window on the Molecular Machinery of Life', at
the University of Leiden, commented: "The Cyttron consortium, of which
Bruker AXS is a key partner, aims to extend and integrate existing
technology platforms in structural biology, with the ultimate aim of
visualizing and modeling living cells with atomic resolution.

laue refinement

Aurora-A is an
oncogenic serine/threonine kinase with a key role in cell division . provides high-level
structural biology services to advance the drug discovery efforts of its
clients .

ortep visualising

This laboratory will incorporate robotic facilities for the
high-throughput preparation of protein crystallization screens,
combined with the Crystal Farm(TM) incubation and imaging system for
crystal growth.

interconversion laue

"The Protein Portfolio allows companies without
internal structural biology resources to rapidly determine specific
information about how their molecules bind, information that translates
directly into accelerating the design of improved chemical entities."

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker
Daltonics Inc.

coppens crystallographic

V.

geometrical ifo

"
ActiveSight plans to add additional kinases, nuclear hormone receptors,
and proteases to the Protein Portfolio which already includes human Hsp90 and
Fructose-1,6-bisphosphatase. The
research facilities which Bruker AXS has made available to the
partners of the Cyttron consortium are absolutely essential for
reaching this objective.

crystallography amorphous

Consequently, Aurora is the target of a number of active drug discovery
programs . Medicinal chemists can submit their lead compounds and
receive important structural information within weeks," states Ronald V.

ABOUT ACTIVESIGHT
ActiveSight(TM), a division of Rigaku /MSC, Inc.

visualizing xact

For more information visit http://www.bruker-biosciences.

snb coppens

Gyrase B, the target of existing
quinolone and coumarin antibiotics, is the subject of active research to find
novel inhibitors .

crystallography crystallographic

coppens ortep

SAN DIEGO, ActiveSight, provider of protein
crystallography services, has expanded their portfolio of "ready-to-go"
proteins to include three new members: the human kinase Aurora-A , the nuclear
hormone receptor FXR, and the bacterial enzyme DNA Gyrase B.

ifo coppens

ActiveSight Introduces Protein Crystal Targets for Oncology Cardiovascular and Anti-infective Research

ActiveSight features human target proteins available for rapid
co-crystallization and in-house structural determination . By further strengthening our ties with the
structural biology community in Europe and beyond, this lab will drive
the development of new applications and technologies.

irix umwege

For more information: www .

interconversion richardsons

crystallographic visualise

ortep xtal

Eric Hovestreydt, Managing Director of Bruker AXS B.

amorphous snb

newscom.
Dr.

crystallography geometrical

com/cgi-bin/prnh/20050317/LATH075 )
The new targets cover a variety of therapeutic areas. The X-ray Life-Sciences Laboratory is part
of our continuing commitment to develop state-of-the-art tools for
structural proteomics . Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties.

irix crystallographic

and Bruker AXS Inc.

coppens interconversion

com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not
describe historical facts may constitute forward -looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. We disclaim any intent or obligation to update
these forward-looking statements.

diffraction ortep

Bruker AXS is a leading developer
and provider of life science and advanced materials research tools
based on x-ray technology.
Bruker Daltonics also offers a broad line of nuclear, biological and
chemical (NBC) detection products for defense and homeland security.

geometrical irix

com/

Bruker AXS Establishes New X-Ray Life-Sciences Laboratory For Protein Crystallization and Macromolecular Structure Determination

in
Delft, explained: "The X-ray Life-Sciences Laboratory will
continuously improve our X-ray instrumentation, software and methods
through close collaborations with and feedback from the
crystallographers using it.

visualizing xact

Swanson, ActiveSight CSO.active-sight. Bruker Daltonics is a leading developer and
provider of innovative life science tools based on mass spectrometry. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.

lattices amorphous

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)